WeSearch

STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more

Ed Silverman· ·1 min read · 0 reactions · 0 comments · 7 views
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more

The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions

Original article
STAT · Ed Silverman
Read full at STAT →
Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from STAT

STAT+: Up and down the ladder: The latest comings and goings
STAT·9
STAT+: Axsome wins FDA nod for Alzheimer’s agitation
STAT·7
PFAS is still in some infant formula
STAT·7
STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more
STAT·9
Opinion: America is worrying about fertility again. But it’s not really about families
STAT·11
Opinion: The psychedelic revolution is leaving behind people of color
STAT·9